Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Clostridium difficile associated diarrhea (CDAD) is a significant cause of morbidity and
mortality, caused by loss of healthy gut flora. Conventional treatment uses antibiotics to
kill Clostridium difficile. A novel treatment uses replacement of gut flora by fecal
microbiota transplant (FMT). Randomized trials have established safety and efficacy of FMT in
recurrent CDAD, but no trial has used FMT for primary CDAD. This study will randomize
patients to oral encapsulated FMT or oral Vancomycin.